Dual stimulation using corifollitropin alfa in 54 Bologna criteria poor ovarian responders - a case series.


Journal

Reproductive biomedicine online
ISSN: 1472-6491
Titre abrégé: Reprod Biomed Online
Pays: Netherlands
ID NLM: 101122473

Informations de publication

Date de publication:
May 2019
Historique:
received: 25 05 2018
revised: 01 01 2019
accepted: 04 01 2019
pubmed: 24 2 2019
medline: 28 4 2020
entrez: 24 2 2019
Statut: ppublish

Résumé

What are the reproductive outcomes of Bologna criteria poor responders undergoing dual stimulation (DuoStim) and subsequent cryopreserved embryo transfer? Case series of patients treated during the period August 2015 to March 2018 in a public fertility clinic. The study included 54 Bologna criteria poor responder IVF patients younger than 42 years receiving a follicular stimulation (DuoStim 1) followed by a luteal phase stimulation (DuoStim 2) within the same cycle, both stimulations being performed with corifollitropin alfa followed by a subsequent cryopreserved embryo transfer cycle. The primary endpoint was the number of oocytes retrieved in DuoStim 1 compared with DuoStim 2. The secondary endpoint was ongoing pregnancy rate (OPR) at 12 weeks of gestation. The mean number of oocytes retrieved in DuoStim 1 and DuoStim 2 was 2.4 ± 2.1 versus 3.7 ± 2.6, respectively; thus, a total of 1.2 (95% CI, 0.46-1.96) more oocytes was retrieved in DuoStim 2 compared with DuoStim 1 (P = 0.002). The OPR at 12 weeks was 20% (11/54) in this poor ovarian response population with a mean age of 36.7 years. Luteal phase stimulation results in more oocytes in poor responders compared with follicular phase stimulation. DuoStim, using corifollitropin alfa followed by individualized FSH dosing, appears to be an alternative to conventional follicular phase stimulation, decreasing the risk of cycle cancellation.

Identifiants

pubmed: 30795977
pii: S1472-6483(19)30057-4
doi: 10.1016/j.rbmo.2019.01.007
pii:
doi:

Substances chimiques

Follicle Stimulating Hormone, Human 0
follicle stimulating hormone, human, with HCG C-terminal peptide 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

677-682

Informations de copyright

Copyright © 2019 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Auteurs

Birgit Alsbjerg (B)

The Fertility Clinic, Skive Regional Hospital, Denmark; Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark. Electronic address: alsbjerg@dadlnet.dk.

Thor Haahr (T)

The Fertility Clinic, Skive Regional Hospital, Denmark; Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.

Helle O Elbaek (HO)

The Fertility Clinic, Skive Regional Hospital, Denmark.

Rita Laursen (R)

The Fertility Clinic, Skive Regional Hospital, Denmark.

Betina B Povlsen (BB)

The Fertility Clinic, Skive Regional Hospital, Denmark.

Peter Humaidan (P)

The Fertility Clinic, Skive Regional Hospital, Denmark; Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH